ALX Oncology (ALXO) announced the appointment of Jeff Knight as chief development and operating officer, effective April 13. Most recently, he served as chief development and operating officer at Crinetics (CRNX).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Appoints Jeff Knight to Lead Development
- ALX Oncology initiated with an Overweight at Wells Fargo
- Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation
- ALX Oncology price target raised to $4 from $2 at H.C. Wainwright
- Alx Oncology Earnings Call Highlights Biomarker Momentum